Clin2
NCT06690476Possibly a fitRecruiting

Study of IPM514 for esophageal cancer

Esophageal Squamous Cell Carcinoma

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests a new drug called IPM514 for people with a type of esophageal cancer (squamous cell). It aims to find out if the drug is safe and effective. The trial has different groups for those who have had prior treatment and those who will have surgery after treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
74 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have a confirmed diagnosis of esophageal squamous cell carcinoma.
  • Your cancer has progressed or you cannot tolerate standard treatment (PD-1 antibody with platinum chemo).
  • You have at least one measurable tumor on a scan (CT or MRI).
  • Your general health status (ECOG) is 0 or 1, meaning you are fully active or only limited in strenuous activity.
  • Your blood counts and organ function are within certain limits (checked by blood tests).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07203898Not yet recruiting· Phase 1
Study of IPM514 for advanced esophageal cancer

This trial tests a new drug, IPM514, in people with advanced esophageal squamous cell carcinoma whose cancer has worsened after standard treatments like immunotherapy with PD-1/PD-L1 inhibitors and platinum chemotherapy. It aims to see if IPM514 can help when other options have stopped working.

NCT05319730Recruiting· Phase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer

This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.

Tucson, Arizona
NCT06601309Recruiting· Phase 2
Study of treatments before surgery for esophageal cancer

This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.

Fuzhou, Fujian
NCT06173986Recruiting· Phase 1/Phase 2
Immunotherapy plus chemoradiation for advanced esophageal cancer

This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.

Shanghai
NCT06122493Recruiting· Phase 2
Better treatment for advanced esophageal cancer

This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.

Shanghai, Shanghai Municipality
NCT06780111Recruiting· Phase 1/Phase 2
Combination therapy study for advanced esophageal cancer

This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.

Pittsburgh, Pennsylvania

Hear when a new Esophageal Squamous Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.